JNNP: Effect of Erenumab on functional outcomes in patients with seizure migraines

Erenumab is a monoclonal antibody that inhibits a typical calcitonin gene-related peptide (CGRP) subject.
clinical studies have demonstrated the efficacy and safety of Erenumab in patients with seizure migraines (EM) and chronic migraines (CM), including those who have previously failed to treat preventive migraines.
3b LIBERTY study confirmed that Erenumab is a potential treatment for EM patients with 2-4 preventive measures that are ineffective. An important component of migraine therapy is to assess the headache-related functional damage reported by the patient and measure it against the results reported by the patient (PRO).
the purpose of this analysis was to evaluate the functional results reported by patients with the efficacy of Erenumab and placebo in patients who were ineffective with 2-4 preventive drugs in the Phase 3b LIBERTY study.
results include an assessment of the effects of migraines on daily activity and productivity, as well as an assessment of the results of physical and functional damage.
the analysis was based on data from 3b-, 12-week, randomized, double-blind, placebo-controlled, multi-center, parallel group LIBERTY studies conducted in 16 countries in Europe and Australia from March 20 to October 27, 2017, involving 2-4 EM patients with ineffective preventive drugs.
In short, the study included the screening phase (0 to 2 weeks), the baseline phase (4 weeks), the double blind treatment phase (12 weeks), the continuous open label treatment phase (156 weeks) and the safe follow-up phase (12 weeks).
patients were randomly divided into placebo groups and Erenumab, injected subsultically every 4 weeks at a dose of 140 mg for a ratio of 1:1 for a total of 12 weeks.
the 12-week double-blind treatment phase of the LIBERTY study are eligible to participate in the ongoing open label treatment phase.
this paper reported the results of the 12-week double-blind treatment phase.
patients to complete pro questionnaires using the eDiary platform.
pro-survey patients at home or during outpatient visits during baseline examination and double-blind treatment.
LIBERTY study included nine patients between the ages of 18 and 65 with EM (4 to 14 days a month migraines).
7 eligible patients (1) failed in 2 to 4 preventive treatments: propranolol/metolol, topiramate, fluorocaride, sodium valproate/sodium dipropyrate, amitrilin, venlafasin, reinoply, Candishatan or other locally approved preventive drugs (guiliazine in the Czech Republic; Omecin; Nadolo, Spain; Oktoron in France; fentanyl in Austria, the Czech Republic, France, the Netherlands, Sweden and the United Kingdom) ;(2) at least one is not applicable or applicable: propranolol/metololol, topiramate or fluorogrelline; and (3) failed or did not fit sodium valproate/sodium diprotinate.
liberty study, a total of 246 patients were randomly divided into the placebo group (n-125) and the Erenumab group (n-121).
240 of them (97.6 per cent) completed the double-blind treatment phase.
treatment groups had a good overall balance in baseline demographics and disease characteristics.
mpFID-PI and -EA scores were significantly higher in patients treated with Erenumab than in the placebo group.
week 12, the average change in MPFID-PI (SD) was -1.9 (0.8) and +1.6 (0.8), respectively, compared to the placebo group, and the difference between the treatment groups was -3.5 (-5.7 to -1.2; p=0.003).
mpFID-EA domain correspondence values in the Erenumab group and the placebo group were -3.4 (0.8) and -0.6 (0.8), respectively, and the difference between the treatment groups was -3.9 (-6.1 to -1.7; p.lt;0.001).
At all points in time (i.e., weeks 4, 8 and 12), the change in PI compared to baseline levels and the effect of Erenumab on EA were significant, with both scores in the 140 Mg Erenumab treatment group decreasing compared to the average increase in the two scores in the placebo group at week 12.
in all the parameters measured by WPAI at each evaluation point in time, there was a favourable trend between patients treated with Erenumab (n=119) and those treated with placebo (n=124).
three-quarters of patients who took Erenumab at week 12 had significantly improved the parameters compared to the placebo group.
and disability rates for people with migraines, and there is a high medical need for drugs that meet treatment goals while improving the quality of life.
results of these analyses supplement the erenumab efficacy and safety data obtained from the LIBERTY study.
Lanteri-Minet M, Goadsby PJ, Reuter U, et al Effect of erenumab on functional outcomes in patients with episodic migraine in who 2-4 minutes were not useful: results from the LIBERTY Journal of Neurology, Neurosurgery and PsimsyPublished Online First: 05 January 2021. doi: 10.1136/jnnp-2020-324396MedSci Original Source: MedSci Original Copyright Statement: All noted on this website "Source: Mets Medicine" or "Source: MedSci Original" The copyrights to the text, images and audio-visual materials of Mays Medical shall not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here